Daunorubicine

DRUG5 trials

Conditions

AMLAcute Myeloid LeukemiaChronic Myeloid LeukemiaDe Novo Akute Myeloid Leukemia (AML)ElderlyLeukemia, Myelocytic, AcuteRefractory Anemia With Excess of Blasts in TransformationSecondary Acute Myeloid Leukemia (AML)

Phase 1

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

TerminatedNCT00219765

Poitiers University HospitalChronic Myeloid Leukemia

Start: 2001-05-31End: 2006-01-31Target: 30Updated: 2005-11-28

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

CompletedNCT03563560

Sumitomo Pharma Co., Ltd.Acute Myeloid Leukemia

Start: 2018-05-15End: 2020-03-31Updated: 2022-04-12

Phase 2

Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T

NCT00209833

Hannover Medical SchoolDe Novo Akute Myeloid Leukemia (AML), Refractory Anemia With Excess of Blasts in Transformation, Secondary Acute Myeloid Leukemia (AML)

Start: 1999-01-31End: 2005-09-30Target: 200Updated: 2005-11-18

Phase 3

DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML

CompletedNCT00589082

Gruppo Italiano Malattie EMatologiche dell'AdultoAML, Elderly

Start: 2001-10-31End: 2005-11-30Updated: 2008-01-09

Unknown Phase

AML Treatment in Untreated Adult Patients

NCT00449319

Gruppo Italiano Malattie EMatologiche dell'AdultoLeukemia, Myelocytic, Acute

Start: 1998-11-30End: 2018-07-31Updated: 2017-11-17

Cancer Science2022-06-113 citations

Phase 1 Study of Alvocidib (DSP-2033) in Combination with Cytarabine/Mitoxantrone (ACM) or Cytarabine/Daunorubicin (A+7+3) in Japanese Patients (Pts) with Acute Myeloid Leukemia (AML)

Blood2020-11-041 citations

<i>TET2</i> mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns

Genes Chromosomes and Cancer2014-06-0529 citations

Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications

Blood2013-12-14204 citations

Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia.

2012-12-1248 citations

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

2012-09-1721 citations

Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.

2011-03-0382 citations

FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype.

2011-01-1734 citations

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

2010-12-1031 citations

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

2010-04-26141 citations

Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.

2009-12-2896 citations